GlassScriptPhysician profile
Shane M Burkett
NPI 1750926010
$11,819.78
in general payments reported to CMS, 2019-2025
43 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,496 · 2022: $1,923 · 2023: $2,587 · 2024: $2,644 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,380 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,380.08 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,508.66 | 2021-2025 | Farxiga, Tezspire, Breztri |
| Lilly USA, LLC | $1,235.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,192.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,118.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $887.27 | 2021-2025 | |
| Abbvie INC. | $811.65 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.63 | 2021-2025 | Jardiance, Combivent Respimat, Stiolto Respimat |
| Amgen INC. | $539.52 | 2021-2025 | Repatha, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $434.86 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $422.46 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $356.00 | 2021-2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.20 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $225.91 | 2021-2024 | Trintellix, Glassia |
| Amarin Pharma, INC. | $210.14 | 2021-2022 | |
| Exact Sciences Corporation | $178.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Burkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.